TargetMol

Legumain Protein, Human, Recombinant (His)

Product Code:
 
TAR-TMPY-06640
Product Group:
 
Recombinant Proteins
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
1 / 1
❮❯

Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TMPY-06640-50ug50ugEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Bioactivity:
Legumain Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 49.12 kDa and the accession number is Q99538.
Molecular Weight:
49.12 kDa (predicted)
Purity:
98%

References

1.Schwarz G,et al.(2002) Characterization of legumain. Biol Chem. 383(11): 1813-6. 2.Liu C,et al.(2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63(11): 2957-64. 3.Murthy RV,et al.(2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 11(6): 2293-9. 4.Gawenda J,et al.(2007) Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat. 102(1): 1-6. 5.Clerin V,et al.(2007) Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis. Atherosclerosis. 201(1): 53-66. 6.Lew??n S,et al.(2008) A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother. 57(4): 507-15.